Beone Medicines

This phase 3 study tests whether a new combination of sonrotoclax and zanubrutinib works better than the current standard (venetoclax plus obinutuzumab) for people with untreated chronic lymphocytic leukemia (CLL). About 652 adults with CLL who need treatment but have not receive…

This study tests a drug called zanubrutinib in people with primary membranous nephropathy (PMN), a kidney disease that causes protein leakage in urine. The goal is to see if zanubrutinib can reduce protein levels and lead to remission better than the current standard treatment, t…

This study looks at the long-term safety and effects of certain cancer drugs in people with advanced tumors. Participants must have already been in a related earlier study and still benefit from the treatment. The goal is to track side effects and see how well the drugs work over…

This early-stage trial tests a new drug called BGB-21447 in about 112 people whose B-cell blood cancers (like lymphoma or leukemia) have returned or stopped responding to standard treatments. The main goals are to find a safe dose and check for side effects. Researchers will also…

This study tests a new drug called sonrotoclax, either alone or with another drug (zanubrutinib), in people with Waldenström macroglobulinemia, a slow-growing blood cancer. The goal is to see if the treatment can shrink tumors and control the disease. About 114 adults with either…

This early-phase study tests a new drug called BGB-C354, which delivers a cancer-killing agent directly to tumor cells, alone or with an immunotherapy (tislelizumab). The goal is to find a safe dose and see if it shrinks tumors in people with advanced solid cancers that have not …

This early-phase study tests a new drug, BG-60366, designed to break down a faulty protein (mutant EGFR) that drives non-small cell lung cancer. About 33 adults with advanced or spreading lung cancer who have already tried other treatments will receive the drug to see if it is sa…

This early-phase study tests a new drug called sonrotoclax (BGB-11417) in adults with certain blood cancers (B-cell malignancies) that have come back or not responded to prior treatment. The main goals are to find the safest dose and to check for side effects when given alone or …

This study tests whether adding sonrotoclax to zanubrutinib works better than zanubrutinib alone for adults with untreated chronic lymphocytic leukemia (CLL). About 94 participants will receive either the combination or the single drug. The goal is to see if the combo leads to mo…